Leerink Partners Reiterates Outperform Rating on Oculis Holding AG (OCS)

Leerink Partners analyst Marc Goodman reiterated an Outperform rating and $22.00 price target on Oculis Holding AG (NASDAQ: OCS).

The analyst comments "Bottom Line: Oculis reported 2Q24 numbers and provided updates across its portfolio of novel ocular assets, and everything continues to progress well. We continue to believe that this story remains underappreciated by investors. It has 2 late-stage assets with known mechanisms and licaminlimab has now shown positive PoC as a potential precision medicine in dry eye disease (DED), and we think that both OCS-01 in DME and licaminlimab in DED have a good chance of working and finding important places in their respective markets. We have updated our model based on the print and maintain our Outperform rating and $22 PT."

For an analyst ratings summary and ratings history on Oculis Holding AG click here. For more ratings news on Oculis Holding AG click here.

Shares of Oculis Holding AG closed at $11.99 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• AeroVironment wins $117M Army drone contract
• Oculis Holding AG (OCS) PT Lowered to $26 at H.C. Wainwright